Else looks to develop potential infant formula in U.S.

Executive Summary

• Else Nutrition Holdings Inc. highlights the FDA’s formal inclusion of protein efficiency ratio (PER) rat bioassay study guidance as an active regulatory topic, signaling a major step toward clarity for novel plant-based infant formulas.
• The anticipated PER guidance is expected to reduce regulatory uncertainty, streamline preclinical study requirements, and strengthen the commercial pathway for Else’s plant-based infant formula in the U.S. market.
• The development aligns with broader federal modernization efforts like "Operation Stork Speed," positioning Else to capitalize on structural industry tailwinds and increased demand for non-dairy, plant-based nutrition options.

Key Details

• FDA has formally listed PER rat bioassay study guidance as an active topic within its foods program regulatory agenda.
• PER rat bioassay is a recognized FDA methodology for validating biological protein quality in infant formulas, but current standards are widely viewed as outdated and create uncertainty for novel protein sources.
• New guidance aims to clarify study design, endpoints, and validation expectations, providing improved visibility into the scope, timeline, and cost of required preclinical studies.
• Regulatory clarity directly reduces a key risk factor for Else’s plant-based infant formula, enhancing its potential for FDA clearance and U.S. market entry.
• The update aligns with federal initiatives like "Operation Stork Speed," which seeks to modernize infant formula oversight and update nutrient standards for the first time since 1998.
• Most competitors rely on conventional dairy or soy proteins; the updated PER methodology explicitly benefits novel protein matrices, placing them on a more level regulatory playing field.
• Strategic tailwinds include rising consumer demand for clean-label and plant-based nutrition, federal pushes to expand market competition, and increased regulatory transparency for new product approvals.
• The company believes these developments strengthen its positioning with institutional investors, ESG-focused funds, and growth investors seeking identifiable regulatory catalysts.

Notable Quotes

• Hamutal Yitzhak, CEO and Co-Founder: "The FDA's progress on PER guidance is a meaningful inflection point for Else Nutrition. As clarity increases around the scientific and procedural standards required for novel infant formulas, our regulatory road map becomes sharper, more predictable and increasingly aligned with federal efforts to modernize the U.S. formula market. This development strengthens our confidence in the commercial potential of our infant formula program in the United States."